{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:58:24Z","timestamp":1790056704158,"version":"4.0.1"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy has transformed cancer treatment by promoting durable clinical responses in a proportion of patients; however, treatment still fails in many patients. Innate immune cells play a key role in the response to immunotherapy. Crosstalk between innate and adaptive immune systems drives T-cell activation but also limits immunotherapy response, as myeloid cells are commonly associated with resistance. Hence, innate cells have both negative and positive effects within the tumor microenvironment (TME), and despite investment in early clinical trials targeting innate cells, they have seen limited success. Suppressive myeloid cells facilitate metastasis and immunotherapy resistance through TME remodeling and inhibition of adaptive immune cells. Natural killer (NK) cells, in contrast, secrete inflammatory cytokines and directly kill transformed cells, playing a key immunosurveillance role in early tumor development. Myeloid and NK cells show reciprocal crosstalk, influencing myeloid cell functional status or antigen presentation and NK effector function, respectively. Crosstalk between myeloid cells and the NK immune network in the TME is especially important in the context of therapeutic intervention. Here we discuss how myeloid and NK cell interactions shape anti-tumor responses by influencing an immunosuppressive TME and how this may influence outcomes of treatment strategies involving drugs that target myeloid and NK cells.<\/jats:p>","DOI":"10.3389\/fimmu.2021.633685","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T15:18:49Z","timestamp":1618845529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment"],"prefix":"10.3389","volume":"12","author":[{"given":"Larissa S.","family":"Carnevalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormas","family":"Ghadially","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs: from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00899","article-title":"The role of tumor-associated myeloid cells in modulating cancer therapy","volume":"10","author":"Neophytou","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12976","article-title":"Macrophage targeting: opening new possibilities for cancer immunotherapy","volume":"155","author":"Cassetta","year":"2018","journal-title":"Immunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression","volume":"9","author":"Awad","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni1190","article-title":"Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus","volume":"6","author":"Arnon","year":"2005","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \u201cone for all, all for one\u201d","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01623","article-title":"Natural killer cells in antifungal immunity","volume":"8","author":"Schmidt","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1254546","article-title":"Role of natural killer cells in antibacterial immunity","volume":"9","author":"Schmidt","year":"2016","journal-title":"Exp Rev Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901644","article-title":"Tumor immunoediting by NKp46","volume":"184","author":"Elboim","year":"2010","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.050588297","article-title":"In vivo natural killer cell activities revealed by natural killer cell-deficient mice","volume":"97","author":"Kim","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.06.009","article-title":"Control of metastasis by NK cells","volume":"32","author":"Lopez-Soto","year":"2017","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1038\/ncomms5539","article-title":"Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells","volume":"5","author":"Sathe","year":"2014","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1073\/pnas.1814642116","article-title":"IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses","volume":"116","author":"Santana Carrero","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/eji.201444699","article-title":"IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness","volume":"45","author":"Ziblat","year":"2015","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00403","article-title":"Consequences of the crosstalk between monocytes\/macrophages and natural killer cells","volume":"3","author":"Michel","year":"2012","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e39170","DOI":"10.1371\/journal.pone.0039170","article-title":"Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response","volume":"7","author":"Morandi","year":"2012","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26192","article-title":"Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions","volume":"57","author":"Wu","year":"2013","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041037","article-title":"IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function","volume":"40","author":"Elkabets","year":"2010","journal-title":"Eur J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.01.006","article-title":"Neutrophil Degranulation, Plasticity, and Cancer Metastasis","volume":"40","author":"Mollinedo","year":"2019","journal-title":"Trends Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1232221","DOI":"10.1080\/2162402X.2016.1232221","article-title":"Tumor-associated neutrophils display a distinct N1 profile following TGFbeta modulation: A transcriptomics analysis of pro- vs. antitumor TANs","volume":"5","author":"Shaul","year":"2016","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"eaao4227","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1591","article-title":"Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress","volume":"76","author":"Tohme","year":"2016","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01749","article-title":"The Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis","volume":"11","author":"Masucci","year":"2020","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6248590","DOI":"10.1155\/2018\/6248590","article-title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer","volume":"2018","author":"Han","year":"2018","journal-title":"J Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3453","article-title":"Characterization of tumor infiltrating natural killer cell subset","volume":"6","author":"Levi","year":"2015","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701103R","article-title":"Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer","volume":"32","author":"Bruno","year":"2018","journal-title":"FASEB J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1593\/neo.121758","article-title":"The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer","volume":"15","author":"Bruno","year":"2013","journal-title":"Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00011-018-1181-4","article-title":"Cross talk between natural killer cells and mast cells in tumor angiogenesis","volume":"68","author":"Ribatti","year":"2019","journal-title":"Inflammation Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid-derived suppressor cells\u2019 interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0732","article-title":"STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion","volume":"6","author":"Gotthardt","year":"2016","journal-title":"Cancer Discovery"},{"key":"B51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1753425912453187","article-title":"Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients","volume":"19","author":"Rocca","year":"2013","journal-title":"Innate Immun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"12528","DOI":"10.1038\/ncomms12528","article-title":"Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia","volume":"7","author":"Klose","year":"2016","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12885-019-6045-y","article-title":"Lipid accumulation impairs natural killer cell cytotoxicity and tumor control in the postoperative period","volume":"19","author":"Niavarani","year":"2019","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12150","article-title":"PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma","volume":"7","author":"Beldi-Ferchiou","year":"2016","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0133","article-title":"PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133353","article-title":"Minimal PD-1 expression in mouse and human NK cells under diverse conditions","volume":"130","author":"Judge","year":"2020","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0062","article-title":"PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients","volume":"6","author":"Concha-Benavente","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discovery"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0879","article-title":"CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer","volume":"23","author":"Srivastava","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw570","article-title":"Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy","volume":"28","author":"Makkouk","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801137","article-title":"CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell Proliferation","volume":"203","author":"Vidard","year":"2019","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1599636","DOI":"10.1080\/2162402X.2019.1599636","article-title":"Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells","volume":"8","author":"Ochoa","year":"2019","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Kohrt","year":"2012","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1172\/JCI129689","article-title":"Targeting CD137 enhances the efficacy of cetuximab","volume":"129","author":"Kohrt","year":"2019","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6418","article-title":"CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation","volume":"173","author":"Dalbeth","year":"2004","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.9.3.649-657.2002","article-title":"Activation of human NK cells by staphylococci and lactobacilli requires cell contact-dependent costimulation by autologous monocytes","volume":"9","author":"Haller","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0152","article-title":"Tumor-Associated Monocytes\/Macrophages Impair NK-Cell Function via TGFbeta1 in Human Gastric Cancer","volume":"5","author":"Peng","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046201","article-title":"Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host","volume":"109","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0191358","DOI":"10.1371\/journal.pone.0191358","article-title":"Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0082","article-title":"Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells","volume":"5","author":"Kubo","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1357","article-title":"IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo","volume":"178","author":"Watkins","year":"2007","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900998","article-title":"Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases","volume":"204","author":"Narasimhan","year":"2020","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303175","article-title":"The absence or overexpression of IL-15 drastically alters breast cancer metastasis via effects on NK cells, CD4 T cells, and macrophages","volume":"193","author":"Gillgrass","year":"2014","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e97792","DOI":"10.1172\/jci.insight.97792","article-title":"CSF1R-dependent myeloid cells are required for NK-mediated control of metastasis","volume":"3","author":"Beffinger","year":"2018","journal-title":"JCI Insight"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1157","article-title":"Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells","volume":"6","author":"Spiegel","year":"2016","journal-title":"Cancer Discovery"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0749","article-title":"Control of Metastases via Myeloid CD39 and NK Cell Effector Function","volume":"8","author":"Yan","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.024","article-title":"CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function","volume":"12","author":"Chun","year":"2015","journal-title":"Cell Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141836","article-title":"CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages","volume":"212","author":"Kitamura","year":"2015","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0530","article-title":"CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis","volume":"17","author":"Roblek","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.042671","article-title":"CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization","volume":"284","author":"Roca","year":"2009","journal-title":"J Biol Chem"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910856117","article-title":"CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas","volume":"117","author":"Flores-Toro","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.04.004","article-title":"Production of interferon-gamma by myeloid cells\u2014fact or fancy","volume":"27","author":"Bogdan","year":"2006","journal-title":"Trends Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)02005-1","article-title":"IFN-gamma production by antigen-presenting cells: mechanisms emerge","volume":"22","author":"Frucht","year":"2001","journal-title":"Trends Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1066","article-title":"STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1","volume":"26","author":"Proia","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","first-page":"334ra52","DOI":"10.1126\/scitranslmed.aad8307","article-title":"Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses","volume":"8","author":"Welters","year":"2016","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccell.2019.08.003","article-title":"Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis","volume":"36","author":"Jackstadt","year":"2019","journal-title":"Cancer Cell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282","article-title":"IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0204","article-title":"NK Cells Control Tumor-Promoting Function of Neutrophils in Mice","volume":"6","author":"Ogura","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-20-0312","article-title":"Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity","volume":"9","author":"Richmond","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0188","article-title":"CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma","volume":"4","author":"Chao","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"839684","DOI":"10.1155\/2015\/839684","article-title":"Chemokine receptor expression on normal blood CD56(+) NK cells elucidates cell partners that comigrate during the innate and adaptive immune responses and identifies a transitional NK cell population","volume":"2015","author":"Lima","year":"2015","journal-title":"J Immunol Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-017-0292-8","article-title":"Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma","volume":"5","author":"Kremer","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/ncomms6639","article-title":"Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients","volume":"5","author":"Ali","year":"2014","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e001006","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.633685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T15:18:54Z","timestamp":1618845534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.633685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":118,"alternative-id":["10.3389\/fimmu.2021.633685"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.633685","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"article-number":"633685"}}